Johannes Nippgen

5.7k total citations · 1 hit paper
27 papers, 4.3k citations indexed

About

Johannes Nippgen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Johannes Nippgen has authored 27 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 6 papers in Genetics. Recurrent topics in Johannes Nippgen's work include Colorectal Cancer Treatments and Studies (12 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer Treatment and Pharmacology (5 papers). Johannes Nippgen is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer Treatment and Pharmacology (5 papers). Johannes Nippgen collaborates with scholars based in Germany, United States and Italy. Johannes Nippgen's co-authors include Eric Van Cutsem, Christopher Stroh, Philippe Rougier, Sabine Tejpar, Geert D’Haens, Tamás Pintér, J. Załuski, Anatoly Makhson, G. Bodoky and Erika Hitre and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

Johannes Nippgen

27 papers receiving 4.1k citations

Hit Papers

Cetuximab and Chemotherap... 2009 2026 2014 2020 2009 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
    2009 2.9k citations Eric Van Cutsem, Claus-Henning Köhne et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Johannes Nippgen Germany 15 3.2k 1.4k 922 898 782 27 4.3k
M. Mueser France 10 3.8k 1.2× 1.9k 1.3× 708 0.8× 779 0.9× 795 1.0× 18 4.5k
Dominik Paul Modest Germany 36 3.5k 1.1× 1.6k 1.1× 1.1k 1.2× 900 1.0× 620 0.8× 206 4.4k
Mark Kozloff United States 36 3.2k 1.0× 1.7k 1.2× 593 0.6× 454 0.5× 1.3k 1.7× 125 4.7k
J. Randolph Hecht United States 22 2.8k 0.9× 1.9k 1.3× 617 0.7× 548 0.6× 949 1.2× 78 4.2k
Dirk Laurent Germany 26 3.0k 0.9× 1.5k 1.0× 804 0.9× 921 1.0× 1.5k 2.0× 76 4.7k
Angela Zubel Germany 21 4.8k 1.5× 2.0k 1.4× 1.4k 1.5× 1.2k 1.4× 1.4k 1.7× 34 5.8k
Tamás Pintér Hungary 18 4.6k 1.4× 2.7k 1.9× 882 1.0× 814 0.9× 908 1.2× 51 5.9k
Sabine Tejpar Belgium 28 4.1k 1.3× 1.9k 1.3× 1.7k 1.8× 929 1.0× 927 1.2× 78 5.3k
Christiane Langer United States 13 4.6k 1.4× 2.0k 1.4× 1.5k 1.7× 962 1.1× 1.1k 1.4× 26 5.8k
Shirin Khambata‐Ford United States 16 4.5k 1.4× 2.2k 1.5× 1.6k 1.7× 730 0.8× 1.1k 1.5× 34 5.5k

Countries citing papers authored by Johannes Nippgen

Since Specialization
Citations

This map shows the geographic impact of Johannes Nippgen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johannes Nippgen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johannes Nippgen more than expected).

Fields of papers citing papers by Johannes Nippgen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johannes Nippgen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johannes Nippgen. The network helps show where Johannes Nippgen may publish in the future.

Co-authorship network of co-authors of Johannes Nippgen

This figure shows the co-authorship network connecting the top 25 collaborators of Johannes Nippgen. A scholar is included among the top collaborators of Johannes Nippgen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johannes Nippgen. Johannes Nippgen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sobrero, Alberto F., Heinz‐Josef Lenz, Cathy Eng, et al.. (2020). Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. The Oncologist. 26(2). e261–e269. 12 indexed citations
2.
Sobrero, Alberto F., Heinz‐Josef Lenz, Cathy Eng, et al.. (2019). Retrospective analysis of overall survival (OS) by subsequent therapy in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving irinotecan ± cetuximab in the EPIC study.. Journal of Clinical Oncology. 37(15_suppl). 3580–3580. 3 indexed citations
3.
Hakenberg, Oliver W., José Luis Perez‐Gracia, Daniel Castellano, et al.. (2018). Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. European Journal of Cancer. 107. 186–195. 10 indexed citations
4.
Sobrero, Alberto F., Heinz‐Josef Lenz, Cathy Eng, et al.. (2018). Retrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC). Annals of Oncology. 29. viii163–viii163. 1 indexed citations
5.
Wagner, Andrew J., Hedy L. Kindler, Hans Gelderblom, et al.. (2016). A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Annals of Oncology. 28(3). 541–546. 44 indexed citations
6.
Chiorean, E. Gabriela, Christopher Sweeney, Hagop Youssoufian, et al.. (2014). A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 73(3). 595–604. 50 indexed citations
7.
Fiedler, Walter, Cristiana Sessa, Luca Gianni, et al.. (2013). First-in-human phase I study of CetuGEX, a novel anti-EGFR monoclonal antibody (mAb) with optimized glycosylation and antibody dependent cellular cytotoxicity.. Journal of Clinical Oncology. 31(15_suppl). 3008–3008. 1 indexed citations
8.
Tap, William D., Brian Andrew Van Tine, Anthony Elias, et al.. (2012). A phase Ib/II study evaluating the efficacy of doxorubicin (D) with or without a human anti-PDGFRα monoclonal antibody olaratumab (IMC-3G3) in the treatment of advanced soft tissue sarcoma (STS).. Journal of Clinical Oncology. 30(15_suppl). TPS10099–TPS10099. 2 indexed citations
9.
Cutsem, Eric Van, Claus-Henning Köhne, Erika Hitre, et al.. (2009). Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. New England Journal of Medicine. 360(14). 1408–1417. 2902 indexed citations breakdown →
10.
Raoul, Jean‐Luc, Jean‐Luc Van Laethem, Marc Peeters, et al.. (2009). Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer. 9(1). 112–112. 41 indexed citations
11.
Tejpar, Sabine, Marc Peeters, Hans Gelderblom, et al.. (2008). Relationship of efficacy with kras status (wild type [wt] vs mutant [mt]) in patients with irinotecan-refractory metastatic colorectal cancer (mcrc), treated with irinotecan and escalating doses of cetuximab: preliminary data from the everest study. Annals of Oncology. 19. 125–125. 1 indexed citations
12.
Tejpar, Sabine, Marc Peeters, Yves Humblet, et al.. (2008). The EVEREST study: relationship between efficacy and K-RAS mutation status in patients with irinotecan-refactory MCRC treated with irinotecan and standard or escalating doses of cetuximab. Ghent University Academic Bibliography (Ghent University). 4 indexed citations
13.
Bokemeyer, Carsten, Igor Bondarenko, J.T. Hartmann, et al.. (2008). KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. Journal of Clinical Oncology. 26(15_suppl). 4000–4000. 181 indexed citations
14.
Oliveira‐Ferrer, Leticia, Jessica Hauschild, Walter Fiedler, et al.. (2008). Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. Journal of Experimental & Clinical Cancer Research. 27(1). 86–86. 93 indexed citations
15.
Cervantes, Andrés, Teresa Macarulla, Erika Martinelli, et al.. (2008). Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 26(15_suppl). 4129–4129. 17 indexed citations
16.
Stupp, Roger, Roland Goldbrunner, Bart Neyns, et al.. (2007). Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology. 25(18_suppl). 2000–2000. 37 indexed citations
17.
Cutsem, Eric Van, Marek P. Nowacki, István Láng, et al.. (2007). Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. Journal of Clinical Oncology. 25(18_suppl). 4000–4000. 233 indexed citations
18.
Hakenberg, Oliver W., Johannes Nippgen, Michael Froehner, Stefan Zastrow, & Manfred P. Wirth. (2006). Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. British Journal of Urology. 98(6). 1225–1227. 72 indexed citations
19.
Meye, Axel, et al.. (2005). Expression of Ki‐67 in squamous cell carcinoma of the penis. British Journal of Urology. 96(1). 146–148. 26 indexed citations
20.
Nippgen, Johannes, Oliver W. Hakenberg, Andreas Manseck, & Manfred P. Wirth. (2001). Spontaneous late rupture of orthotopic detubularized ileal neobladders: report of five cases. Urology. 58(1). 43–46. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Mueser Breakdown of academic impact, for papers by Dominik Paul Modest Breakdown of academic impact, for papers by Mark Kozloff Breakdown of academic impact, for papers by J. Randolph Hecht Breakdown of academic impact, for papers by Dirk Laurent Breakdown of academic impact, for papers by Angela Zubel Breakdown of academic impact, for papers by Tamás Pintér Breakdown of academic impact, for papers by Sabine Tejpar Breakdown of academic impact, for papers by Christiane Langer Breakdown of academic impact, for papers by Shirin Khambata‐Ford
Rankless by CCL
2026